Steatotic Liver Disease in Younger Adults is Associated With Altered Gut Microbiology DOI Creative Commons

Yasmina Tashkent,

Jocelyn M. Choo,

Alyson Richard

и другие.

Liver International, Год журнала: 2025, Номер 45(3)

Опубликована: Фев. 25, 2025

ABSTRACT Background and Aims Steatotic liver disease (SLD) is a leading cause of chronic worldwide. As SLD pathogenesis has been linked to gut microbiome alterations, we aimed identify SLD‐associated features early in development by utilising highly characterised cohort community‐dwelling younger adults. Methods Results At age 27 years, 588 participants the Raine Study Generation 2 underwent cross‐sectional assessment. Hepatic steatosis was quantified using validated magnetic resonance imaging (MRI) volumetric fat fraction (VLFF) equation (HepaFat). Of participants, 488 (83%) were classified as having ‘no SLD’ (VLFF ≤ 3.55%), 76 (12.9%) with ‘mild–moderate’ (VLFF: 3.56%–13.4%) 24 (4.10%) ‘severe’ > 13.4%). Stool profiling identified an association between severe lower microbiota alpha diversity (observed [ p = 0.015], Pielou evenness 0.001] Shannon 0.002]) compared no SLD. Faecal composition differed significantly both mild–moderate ( 0.004) groups 0.001). There significant difference dispersion groups. Reduced relative abundance short‐chain fatty acid producing bacteria, higher levels proinflammatory bacterial taxa, associated q < 0.05). Conclusions adults reduced intestinal microbial pattern taxa depletion that consistent other inflammatory conditions. Our characterisation characteristics provides potential basis for risk identification reduction. Trial Registration The registered Australian New Zealand Clinical Trials Registry (ACTRN12617001599369)

Язык: Английский

Global incidence and prevalence of nonalcoholic fatty liver disease DOI Creative Commons

Margaret LP Teng,

Cheng Han Ng, Daniel Q. Huang

и другие.

Clinical and Molecular Hepatology, Год журнала: 2022, Номер 29(Suppl), С. S32 - S42

Опубликована: Дек. 15, 2022

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of worldwide. The estimated global incidence NAFLD 47 cases per 1,000 population and higher among males than females. prevalence adults 32% (40%) compared to females (26%). has increased over time, from 26% in studies 2005 or earlier 38% 2016 beyond. varies substantially by world region, contributed differing rates obesity, genetic socioeconomic factors. exceeds 40% the Americas South-East Asia. projected increase significantly multiple regions 2030 if current trends are left unchecked. In this review, we discuss future projections.

Язык: Английский

Процитировано

349
Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten? DOI Creative Commons
Chrysi Koliaki, Μaria Dalamaga, Stavros Liatis

и другие.

Current Obesity Reports, Год журнала: 2023, Номер 12(4), С. 514 - 527

Опубликована: Окт. 2, 2023

To provide an update on current obesity prevalence trends and summarize the available evidence suggesting a possible plateau or stabilization in rates after previous sudden global rise.The escalating epidemic represents one of most serious public health challenges. There have been some indications that high-income populations, rate increase adults has stabilized decade 2000-2010, plateau. Current also suggests children adolescents economically advanced countries since 2000, which is possibly related to healthier dietary habits increased levels physical activity. On other hand, there steady uninterrupted rise low-income nations, universal trend escalation rather than slowdown, mainly driven by sharp increases populations. Furthermore, increasing number high- middle-income are currently experiencing severe obesity. In expected double its from 10 20% between 2020 2035, posing enormous threat for healthcare systems. Even if transiently stabilized, remains globally at unacceptably high levels, no guarantee stability (if any) will be maintained long. this review, we explore underlying drivers epidemic; explanations reported slowdown countries; overall take critical perspective hypothesis, emphasizing urgent need immediate effective actions population regional level order halt alarming risks.

Язык: Английский

Процитировано

170
Lifestyle interventions in nonalcoholic fatty liver disease DOI
Zobair M. Younossi, Shira Zelber‐Sagi, Linda Henry

и другие.

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2023, Номер 20(11), С. 708 - 722

Опубликована: Июль 4, 2023

Язык: Английский

Процитировано

149
Epidemiology of Metabolic Dysfunction Associated Steatotic Liver Disease DOI Creative Commons
Zobair M. Younossi,

Markos Kalligeros,

Linda Henry

и другие.

Clinical and Molecular Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Авг. 19, 2024

As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does prevalence metabolic dysfunction associated steatotic liver disease (MASLD). Currently, 38% all adults 7-14% children adolescents have MASLD. By 2040, MASLD rate for is projected over 55%. Although many with will not develop progressive disease, given vast number patients MASLD, it has now become top indication transplant in United States those hepatocellular carcinoma (HCC) women. However, most common cause mortality among remains death cardiovascular diseases. In addition outcomes (cirrhosis HCC), increased risk developing de-novo T2D, chronic kidney sarcopenia extrahepatic cancers. Furthermore, decreased health related quality life, work productivity, fatigue healthcare resource utilization substantial economic burden. Similar other lifestyle interventions heathy diet physical activity remain cornerstone managing these patients. a T2D drugs are available treat co-morbid Resmetirom only MASH-targeted medication that was recently approved by Federal Drug Administration use stage 2-3 fibrosis. The following review provides an overview epidemiology, its factors demonstrates without further global initiatives, may increase.

Язык: Английский

Процитировано

76
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes DOI
Zobair M. Younossi, Pegah Golabi, Jillian Kallman Price

и другие.

Clinical Gastroenterology and Hepatology, Год журнала: 2024, Номер 22(10), С. 1999 - 2010.e8

Опубликована: Март 21, 2024

Язык: Английский

Процитировано

73
Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments DOI Open Access
Hidekatsu Yanai,

Hiroki Adachi,

Mariko Hakoshima

и другие.

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(20), С. 15473 - 15473

Опубликована: Окт. 23, 2023

Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a chronic that affects more than quarter of the global population and whose prevalence increasing worldwide due to pandemic obesity. Obesity, impaired glucose metabolism, high blood pressure atherogenic dyslipidemia are risk factors for MASLD. Therefore, insulin resistance may be closely associated with development progression Hepatic entry increased fatty acids released from adipose tissue, increase in acid synthesis reduced oxidation hepatic overproduction triglyceride-rich lipoproteins induce Since also induces atherosclerosis, leading cause death MASLD patients cardiovascular disease. Considering diseases determines prognosis patients, therapeutic interventions should reduce body weight improve coronary factors, addition an improving function. Lifestyle modifications, such as improved diet exercise, surgical interventions, bariatric surgery intragastric balloons, have shown by reducing weight. Sodium cotransporter 2 inhibitors (SGLT2i) glucagon-like peptide-1 receptor agonists (GLP-1RAs) been suppress occurrence diseases. Both SGLT2i GLP-1 reported enzymes, steatosis fibrosis. We recently selective peroxisome proliferator-activated receptor-alpha (PPARα) modulator pemafibrate PPARα multiple anti-atherogenic properties. Here, we consider pathophysiology mechanisms action drugs whether combination therapy could treatments

Язык: Английский

Процитировано

54
Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study DOI
Matina Kouvari, Laura Valenzuela‐Vallejo, Valentina Guatibonza-García

и другие.

Metabolism, Год журнала: 2023, Номер 147, С. 155666 - 155666

Опубликована: Июль 30, 2023

Язык: Английский

Процитировано

50
Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease DOI
James A. Thomas, Bradley J. Kendall, Hashem B. El–Serag

и другие.

˜The œLancet. Gastroenterology & hepatology, Год журнала: 2024, Номер 9(2), С. 159 - 169

Опубликована: Янв. 9, 2024

Язык: Английский

Процитировано

48
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis DOI Creative Commons
Michael H. Le, David Le,

Thomas C. Baez

и другие.

Clinical and Molecular Hepatology, Год журнала: 2024, Номер 30(2), С. 235 - 246

Опубликована: Янв. 29, 2024

Nonalcoholic fatty liver disease (NAFLD) is associated with a multitude of adverse outcomes. We aimed to estimate the pooled incidence NAFLD-related events.

Язык: Английский

Процитировано

26
Hepatocellular Carcinoma Incidence and Mortality in the USA by Sex, Age, and Race: A Nationwide Analysis of Two Decades DOI Open Access
Yazan Abboud,

Mohamed Ismail,

Hamza Khan

и другие.

Journal of Clinical and Translational Hepatology, Год журнала: 2024, Номер 000(000), С. 000 - 000

Опубликована: Янв. 2, 2024

Background and AimsWhile the incidence rates of hepatocellular carcinoma (HCC) are increasing, there limited comprehensive data on demographic-specific mortality trends in USA. We aimed to evaluate recent HCC among different demographic groups

Язык: Английский

Процитировано

20